Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9419
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHa Park, Joung-
dc.contributor.authorJae Cha, Min-
dc.contributor.authorChoi, Hyewon-
dc.contributor.authorKim, Min-Chul-
dc.contributor.authorChung, Jin-Won-
dc.contributor.authorLee, Kyu-Sun-
dc.date.accessioned2024-12-20T03:01:28Z-
dc.date.available2024-12-20T03:01:28Z-
dc.date.issued2022-12-01-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9419-
dc.description.abstractAbstract Background: It remains unclear whether high titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies aggravate clinical manifestations in patients or whether severe clinical manifestations result in high antibody titers. Thus, we investigated the causeeeffect relationship between SARS-CoV-2 antibody titers and disease severity. Methods: We prospectively enrolled patients admitted with the diagnosis of coronavirus disease-19 (COVID-19) from February 2020 to August 2020. We measured SARS-CoV-2 antibody titers, namely anti-receptor-binding domain (RBD) antibody and neutralizing antibody (NAb), from blood samples and calculated the chest radiograph (CXR) scores of the patients to evaluate the severity of COVID-19. Results: Overall, 40 patients with COVID-19 were enrolled. Pneumonia was observed in more than half of the patients (25/40, 60%). SARS-CoV-2 antibody titers were higher in patients who were aged >60 years (anti-RBD antibodies, P Z 0.003 and NAb, P Z 0.009), presented with pneumonia (P Z 0.006 and 0.007, respectively), and required oxygen therapy (P Z 0.003 and 0.004, respectively) than in those who were not. CXR scores peaked (at 15e21 days after the onset of symptoms) statistically significantly earlier than SARS-CoV-2 antibody titers (at 22e30 days for NAb and at 31e70 days for anti-RBD antibody). There was a close correlation between the maximum CXR score and the maximum SAR-CoV-2 antibody titer. Conclusions: Based on the comparison of the peak time of SARS-CoV-2 antibody titers with the CXR score after symptom onset, we suggest that severe clinical manifestations result in high titers of SARS-CoV-2 antibodies.en_US
dc.language.isoenen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectSARS-CoV-2;en_US
dc.subjectCOVID-19;en_US
dc.subjectDisease severity;en_US
dc.subjectAntibody titeren_US
dc.titleRelationship between SARS-CoV-2 antibody titer and the severity of COVID-19en_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 6 Part 1 2022

Files in This Item:
File Description SizeFormat 
1094-1100.pdf521.46 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.